Trial Profile
An Evaluation of tumor response to osimertinib by early FDG-PET finding in patients with T790M positive EGFR mutated non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Diagnostic use
- 04 Dec 2022 Status changed from recruiting to discontinued.
- 06 Jun 2017 New trial record